Lymphoplasmacytic Lymphoma with IgG or IgA Paraprotein: A Study of 29 Cases including Cases that Can Mimic Plasma Cell Neoplasms.
暂无分享,去创建一个
T. McDonnell | L. Medeiros | M. J. You | Shaoying Li | P. Lin | Sheeba K. Thomas | B. Thakral | Wei Wang | Andrés E Quesada | Jie Xu | Lianqun Qiu | Okechukwu V Nwogbo | C. Ramos | Wei Wang | S. Thomas
[1] A. Panizo,et al. Concomitant lymphoplasmacytic lymphoma, multiple myeloma, and amyloidosis: A diagnostic and therapeutic challenge , 2022, Clinical case reports.
[2] B. Sander,et al. Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non‐Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study , 2021, British journal of haematology.
[3] T. Liehr. International System for Human Cytogenetic or Cytogenomic Nomenclature (ISCN): Some Thoughts , 2021, Cytogenetic and Genome Research.
[4] S. Treon,et al. A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia , 2020, Leukemia & lymphoma.
[5] P. Lin,et al. Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis. , 2019, Pathology.
[6] L. Baldini,et al. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network , 2019, American journal of hematology.
[7] Z. Estrov,et al. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments , 2019, British journal of haematology.
[8] L. Medeiros,et al. Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma , 2017, Modern Pathology.
[9] M. Zimmerman,et al. Concomitant lymphoplasmacytic lymphoma and plasma cell myeloma, a diagnostic challenge. , 2017, American journal of blood research.
[10] K. Patel,et al. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. , 2016, Clinical lymphoma, myeloma & leukemia.
[11] R. Kyle,et al. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations. , 2016, American journal of clinical pathology.
[12] R. Advani,et al. The World Health Organization Classification of Lymphoid Neoplasms , 2013 .
[13] K. Young,et al. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression , 2016, Leukemia & lymphoma.
[14] C. Dinardo,et al. Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies , 2015, Modern Pathology.
[15] W. Morice,et al. Immunophenotypic features by multiparameter flow cytometry can help distinguish low grade B‐cell lymphomas with plasmacytic differentiation from plasma cell proliferative disorders with an unrelated clonal B‐cell process , 2015, British journal of haematology.
[16] L. Medeiros,et al. Potential therapeutic biomarkers in plasma cell myeloma: A flow cytometry study , 2013, Cytometry. Part B, Clinical cytometry.
[17] E. Kulbacki,et al. Concomitant Waldenstrom macroglobulinemia and IgA plasmablastic myeloma in a patient with untreated IgM paraproteinemia: sequential development of biclonal B-cell neoplasms over a 10-year period in a single individual. , 2012, Human Pathology.
[18] T. Molina,et al. Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation. , 2011, American journal of clinical pathology.
[19] L. Medeiros,et al. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. , 2005, American journal of clinical pathology.
[20] R. Bataille,et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. , 2002, Blood.